Savara has announced that it will develop its Molgradex inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of nontuberculous mycobacterial (NTM) lung infection and plans to initiate a Phase 2a trial for that indication in early 2018.
The company is also developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis (PAP) and the Phase 3 IMPALA trial in patients with PAP is underway.
Molgradex was initially developed by Serendex which was acquired by Savara in 2016.
Savara CEO Rob Neville said, “Our goal is to build Savara into a leading specialty pharmaceutical company in the field of orphan lung diseases and we are excited to announce the indication expansion of Molgradex for the treatment of NTM, a serious lung infection affecting tens of thousands of individuals in the United States. Resistance to antibiotics in general is an increasing problem globally, and we are thrilled to embark on this new project targeting NTM lung infection with a very novel approach that targets the lungs’ immune cells and can avoid the problems of antibiotic resistance.”
Read the Savara press release.
